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Cancer is a disease in which a group of cells show an uncontrolled growth (Cell 
division beyond the normal range), invasion (Penetration into and destruction of 
adjacent tissues), and in some cases, metastasis (Spreading to other parts of the body 
via lymph or blood systems). These three destructive nature of cancerous tumors 
distinguish them from benign tumors. Undoubtedly, early detection of cancer is 
associated with an increased survival of these patients. 
Introduction  
SPECT/CT (Single Photon Emission Computed Tomography) give us a signal for 
cancer diagnosis. The use of radiopharmaceuticals such as technetium improves 
images. Technetium is one of the famous contrast agent used in this technique, 
which is toxic and should be used as a complex with a ligand.  
In this study (Technetium-99m)-(DOTA-NHS-ester)-Methionine radio drug was 
synthesized. Technetium-99m is an isomer of isotope-99mTC, which is attempted by 
isomeric transition. Methionine is an essential amino acid which has important roles 
in cancerous cells. DOTA was used to conjugate with Methionine and then labeled 
with 99mTc to improve tumor selectivity. This synthesized radio drug would be able 
to nominate as a SPECT-CT imaging candidate. 
Methods and results 
In this current study, a novel structure of DOTA-NHS ester conjugated to essential 
amino acid methionine was synthesized, and then labeled by a radionuclide 
technetium. The final radiopharmaceutical characterized and then studied as a 
contrast agent in SPECT/CT   imaging.  
Conclusion 
(Technetium-99m)-(DOTA-NHS-ester)-Methionine synthesized radio drug showed 
significant (P<0.05) Cellular uptake in cancerous cells in comparison with other 
normal cells and Cellular toxicity was observed in those cancerous cell lines.  
According to the final data, the synthesized radiopharmaceutical, was detected in the 
tumor with high and significant appearance in SPECT/CT technique. 
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